Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an update.
China Resources Pharmaceutical Group Ltd. announced that its subsidiary, CR Pharmaceutical Commercial, has received approval from the National Association of Financial Market Institutional Investors to issue medium term notes in China. The registration allows for the issuance of up to RMB3 billion in notes over two years, with proceeds intended for repaying interest-bearing debt, potentially impacting the company’s financial stability and market positioning.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products and services in China.
YTD Price Performance: -13.65%
Average Trading Volume: 16,037,765
Technical Sentiment Signal: Sell
Current Market Cap: HK$30.09B
For an in-depth examination of 3320 stock, go to TipRanks’ Overview page.